Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
This study has been terminated.
Information provided by:
First received: December 14, 2005
Last updated: May 23, 2013
Last verified: May 2013
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
Drug: MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
Drug: Placebo / Duration of Treatment: 2 days for screening period
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
|Official Title:||MK0928 Phase II Sleep Laboratory Study - Primary Insomnia|
Further study details as provided by Merck:
Primary Outcome Measures:
- Mean of total sleep time over 2 nights.
Secondary Outcome Measures:
- Mean of other PSG sleep parameters over 2 nights, mean of subjective sleep parameters, and exploratory residual effect.
|Study Start Date:||November 2005|
|Primary Completion Date:||March 2007 (Final data collection date for primary outcome measure)|
Contacts and Locations